Cem Gabay

Q: What Schools Are Affiliated With Cem Gabay

Cem Gabay is affiliated with the following schools: University of California, Berkeley, Stanford University, University of Geneva

Cem Gabay's AcademicInfluence.com Rankings

Cem Gabay

Computer Science

#4355

World Rank

#4585

Historical Rank

Computer Engineering

#28

World Rank

#29

Historical Rank

Computational Linguistics

#400

World Rank

#406

Historical Rank

Machine Learning

#826

World Rank

#837

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Cem Gabay's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Engineering University of California, Berkeley

Similar Degrees You Can Earn

Why Is Cem Gabay Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Cem Gabay's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Acute-phase proteins and other systemic responses to inflammation. (1999) (6193)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010) (4048)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010) (2474)
Interleukin-6 and chronic inflammation (2006) (1218)
Interleukin-1 receptor antagonist: role in biology. (1998) (1049)
IL‐1, IL‐18, and IL‐33 families of cytokines (2008) (808)
IL-1 pathways in inflammation and human diseases (2010) (690)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial (2013) (597)
The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseases. (2015) (358)
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis (2012) (349)
Leptin Signaling Deficiency Impairs Humoral and Cellular Immune Responses and Attenuates Experimental Arthritis1 (2002) (335)
Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. (1997) (327)
Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. (2007) (322)
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. (2009) (310)
IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? (2002) (292)
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics (2014) (278)
IL-36R ligands are potent regulators of dendritic and T cells. (2011) (272)
Interleukin-33 Is Biologically Active Independently of Caspase-1 Cleavage* (2009) (259)
CD14 Is an Acute-Phase Protein1 (2004) (249)
Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. (1997) (246)
Leptin deficiency enhances sensitivity to endotoxin-induced lethality. (1999) (245)
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. (2018) (240)
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. (2017) (240)
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. (2007) (234)
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries (2011) (218)
Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. (2003) (218)
Interleukin-33 biology with potential insights into human diseases (2011) (211)
Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. (2005) (208)
Prevotella copri in individuals at risk for rheumatoid arthritis (2019) (203)
The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. (2006) (192)
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease (2017) (192)
Regulation and function of interleukin‐36 cytokines in homeostasis and pathological conditions (2015) (191)
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. (2009) (190)
Distinct expression of interleukin (IL)‐36α, β and γ, their antagonist IL‐36Ra and IL‐38 in psoriasis, rheumatoid arthritis and Crohn's disease (2015) (187)
IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. (2012) (186)
Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis (2005) (181)
Is IL-1 a good therapeutic target in the treatment of arthritis? (2006) (173)
The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. (2008) (173)
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? (2009) (170)
Leptin directly induces the secretion of interleukin 1 receptor antagonist in human monocytes. (2001) (167)
Systemic rheumatoid vasculitis: a review. (2006) (162)
Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. (1997) (146)
The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes (2006) (136)
Regulation and function of interleukin‐36 cytokines (2018) (135)
The role of leptin in innate and adaptive immune responses (2006) (127)
Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study (2004) (126)
Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. (2007) (120)
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions (2012) (120)
Rituximab in the treatment of antisynthetase syndrome (2005) (115)
Physiologic role of interleukin-1 receptor antagonist (2000) (114)
The Proinflammatory Cytokine Response to Chlamydia trachomatis Elementary Bodies in Human Macrophages Is Partly Mediated by a Lipoprotein, the Macrophage Infectivity Potentiator, through TLR2/TLR1/TLR6 and CD141 (2008) (112)
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis (2015) (112)
Elevated serum levels of free interleukin-18 in adult-onset Still's disease. (2016) (111)
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. (2011) (107)
Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. (2011) (106)
Specific role of interleukin-1 in hepatic neutrophil recruitment after ischemia/reperfusion. (2002) (103)
Cigarette smoking and radiographic progression in rheumatoid arthritis (2007) (102)
Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. (1994) (101)
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement (2012) (101)
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. (2011) (100)
Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis (2007) (100)
Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. (2010) (95)
IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro (2017) (93)
Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. (2018) (88)
Indirect Effects of Leptin Receptor Deficiency on Lymphocyte Populations and Immune Response in db/db Mice1 (2006) (88)
Bone mineral density in patients with end-stage renal failure. (1993) (87)
The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. (2006) (87)
Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. (2012) (87)
Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. (1993) (85)
Leptin deficiency enhances sensitivity to endotoxin-induced lethality. (1999) (82)
Elevated Levels of Tumor Necrosis Factor-Alpha in Periradicular Fat Tissue in Patients With Radiculopathy From Herniated Disc (2008) (81)
Assessment of the efficacy of different statins in murine collagen-induced arthritis. (2004) (79)
Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1beta on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells: differential effect on C-reactive protein production. (1999) (76)
The role of female hormonal factors in the development of rheumatoid arthritis (2016) (75)
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration (2011) (75)
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study (2015) (75)
Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. (2009) (73)
Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo. (1997) (73)
Production of IL‐1 receptor antagonist by hepatocytes is regulated as an acute‐phase protein in vivo (2001) (72)
Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee (2014) (70)
The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases (2009) (68)
A role for leptin in rheumatic diseases? (2003) (68)
Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. (2015) (68)
Effect of particle size on the biodistribution of nano- and microparticles following intra-articular injection in mice. (2016) (65)
Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. (2010) (65)
Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype (2017) (61)
The mouse interleukin (Il)33 gene is expressed in a cell type‐ and stimulus‐dependent manner from two alternative promoters (2012) (60)
Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines. (2016) (60)
Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial. (2010) (60)
Cytokines in the rheumatic diseases. (2004) (59)
Mouse neutrophils express the decoy type 2 interleukin‐1 receptor (IL‐1R2) constitutively and in acute inflammatory conditions (2013) (57)
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients (2012) (57)
Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. (2010) (57)
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study (2008) (57)
Do synovial leptin levels correlate with pain in end stage arthritis? (2013) (55)
The effect of alcohol on radiographic progression in rheumatoid arthritis. (2010) (55)
Myeloid‐Related Proteins 8 and 14 Contribute to Monosodium Urate Monohydrate Crystal–Induced Inflammation in Gout (2014) (55)
IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. (2019) (54)
Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis. (2001) (54)
Delayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient mice (2004) (54)
Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases – a longitudinal study (2015) (53)
Interferon β stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts (2003) (53)
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis (2020) (53)
The severity of experimental arthritis is independent of IL-36 receptor signaling (2013) (51)
Leptin activates the promoter of the interleukin-1 receptor antagonist through p42/44 mitogen-activated protein kinase and a composite nuclear factor kappa B/PU.1 binding site. (2003) (50)
Nanocrystal-Polymer Particles: Extended Delivery Carriers for Osteoarthritis Treatment. (2018) (49)
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis (2017) (47)
Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trial (2011) (47)
Production of interleukin-1 receptor antagonist by human articular chondrocytes (2002) (47)
Inflammasome Adaptor ASC Suppresses Apoptosis of Gastric Cancer Cells by an IL18-Mediated Inflammation-Independent Mechanism. (2018) (46)
β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion. (2018) (44)
Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. (2010) (43)
Cardiovascular risk in patients with rheumatoid arthritis (2017) (43)
Cytokine inhibitors in the treatment of rheumatoid arthritis (2002) (42)
Evaluation of cardiovascular risk in patients with rheumatoid arthritis: Do cardiovascular biomarkers offer added predictive ability over established clinical risk scores? (2012) (42)
Lower level of synovial fluid interferon-gamma in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive arthritis. (2003) (42)
Magnetically retainable microparticles for drug delivery to the joint: efficacy studies in an antigen-induced arthritis model in mice (2009) (42)
Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. (1996) (42)
IL‐1 receptor antagonist (IL‐1Ra) does not inhibit the production of C‐reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumour cells (1995) (41)
Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis (2018) (41)
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration (2016) (40)
Expression and function of junctional adhesion molecule-C in human and experimental arthritis (2007) (40)
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial (2020) (40)
Peptidomimetic Fluoromethylketone Rescues Mice from Lethal Endotoxic Shock (1999) (40)
Anti-RA 33 antinuclear autoantibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and antiperinuclear antibodies. (1993) (39)
At the horizon of innovative therapy in rheumatology: new biologic agents (2008) (39)
Inflammation: IL-36 has proinflammatory effects in skin but not in joints (2014) (39)
Synovial tissues concentrate secreted APRIL (2009) (39)
Variable domain N‐linked glycosylation and negative surface charge are key features of monoclonal ACPA: Implications for B‐cell selection (2018) (38)
Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patients (2010) (38)
Prolonged treatment with Tadekinig alfa in adult-onset Still’s disease (2018) (37)
Treatment of rheumatoid arthritis with IL-1 inhibitors (2004) (37)
Mice transgenic for intracellular interleukin‐1 receptor antagonist type 1 are protected from collagen‐induced arthritis (2003) (37)
Remission of collagen‐induced arthritis is associated with high levels of transforming growth factor‐β expression in the joint (2006) (37)
IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. (2019) (36)
Molecular Characterization and Subcellular Localization of Macrophage Infectivity Potentiator, a Chlamydia trachomatis Lipoprotein (2007) (34)
SIK inhibition in human myeloid cells modulates TLR and IL‐1R signaling and induces an anti‐inflammatory phenotype (2016) (34)
Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency (2013) (33)
Limited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial Infection (2015) (33)
Joint Damage Progression in Patients with Rheumatoid Arthritis in Clinical Remission. Do Biologics Perform Better Than Synthetic Antirheumatic Drugs? (2014) (32)
Acute Phase Proteins (2001) (32)
Hand osteoarthritis: new insights. (2013) (32)
Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study (2015) (32)
A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease (2016) (31)
Occurrence of antiperinuclear, antikeratin, and anti-RA 33 antibodies in juvenile chronic arthritis. (1993) (31)
Discrimination of COVID‐19 From Inflammation‐Induced Cytokine Storm Syndromes Using Disease‐Related Blood Biomarkers (2021) (31)
Spontaneous secretion of interleukin-17 and -22 by human cervical cells in Chlamydia trachomatis infection. (2011) (31)
Soluble interleukin‐6 receptor strongly increases the production of acute‐phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes (1995) (30)
IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis (2020) (30)
Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study (2018) (29)
Type I IL-1 receptor mediates IL-1 and intracellular IL-1 receptor antagonist effects in skin inflammation. (2007) (29)
The Activity of CCL18 is Principally Mediated through Interaction with Glycosaminoglycans (2013) (28)
Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail (2020) (28)
Recommendations for the use of ultrasound in rheumatoid arthritis: literature review and SONAR score experience. (2013) (27)
Severe Neutrophil-Dominated Inflammation and Enhanced Myelopoiesis in IL-33–Overexpressing CMV/IL33 Mice (2015) (27)
Pre-interleukin-1alpha expression reduces cell growth and increases interleukin-6 production in SaOS-2 osteosarcoma cells: Differential inhibitory effect of interleukin-1 receptor antagonist (icIL-1Ra1). (2005) (27)
Endogenous IL-1α is a chromatin-associated protein in mouse macrophages. (2013) (27)
International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. (2017) (27)
Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis. (2006) (26)
Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of Osteoclastogenesis (2017) (26)
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. (2020) (26)
Etanercept in treatment of Felty’s syndrome (2005) (26)
Intracellular interleukin-1 receptor antagonist type 1 antagonizes the stimulatory effect of interleukin-1 alpha precursor on cell motility. (2005) (26)
Biological agents in monotherapy for the treatment of rheumatoid arthritis. (2014) (26)
LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial (2012) (26)
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland (2020) (25)
Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies. (2009) (25)
Comparison of Serological Biomarkers in Rheumatoid Arthritis and Their Combination to Improve Diagnostic Performance (2018) (24)
Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor α agents: an open-label observational study (2006) (24)
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. (2015) (24)
Distinct Roles of Hepatocyte- and Myeloid Cell-Derived IL-1 Receptor Antagonist during Endotoxemia and Sterile Inflammation in Mice (2010) (24)
The Effect of Comedication With a Conventional Synthetic Disease‐Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti–Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis (2016) (23)
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials (2017) (22)
IL-1 inhibitors: novel agents in the treatment of rheumatoid arthritis (2000) (22)
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists (2012) (22)
Circulating levels of IL‐11 and leukaemia inhibitory factor (LIF) do not significantly participate in the production of acute‐phase proteins by the liver (1996) (22)
Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same disease (2012) (21)
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis (2017) (21)
The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes (2004) (21)
IL‐1R1–MyD88 axis elicits papain‐induced lung inflammation (2016) (20)
The role of the IL-1 system in pregnancy and the use of IL-1 system markers to identify women at risk for pregnancy complications† (2020) (19)
Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community. (2006) (19)
Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release system. (2015) (18)
Atherosclerosis severity is not affected by a deficiency in IL‐33/ST2 signaling (2015) (18)
Primary human articular chondrocytes, dedifferentiated chondrocytes, and synoviocytes exhibit differential responsiveness to interleukin‐4: Correlation with the expression pattern of the common receptor gamma chain (2002) (18)
Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins (2010) (18)
Adaptive Immune Response in JAM-C-Deficient Mice: Normal Initiation but Reduced IgG Memory1 (2009) (18)
The advent of biosimilars: challenges and risks. (2014) (18)
Long‐term therapy with anakinra in hidradenitis suppurativa in three patients (2019) (18)
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes (2020) (18)
Anti-inflammatory effects of hepatocyte growth factor: induction of interleukin-1 receptor antagonist. (2004) (17)
AB0451 NI-0101, a Monoclonal Antibody Targeting Toll Like Receptor 4 (TLR4) Being Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine (2015) (17)
Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesis (2017) (17)
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. (2020) (17)
Sulphasalazine-related life-threatening side effects: is N-acetylcysteine of therapeutic value? (1993) (17)
IL-1 trap. Regeneron/Novartis. (2003) (16)
Discrimination of C57BL/6J Rj and 129S2/SvPasCrl inbred mouse strains by use of simple sequence length polymorphisms. (2007) (16)
Articular inflammation is controlled by myeloid cell-derived interleukin 1 receptor antagonist during the acute phase of arthritis in mice (2011) (16)
Mice deficient in hepatocyte‐specific IL‐1Ra show delayed resolution of concanavalin A‐induced hepatitis (2012) (16)
Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study. (2019) (16)
Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries (2018) (16)
Total hip prosthetic joint infection due to Veillonella species. (2004) (16)
Immune-mediated experimental arthritis in IL-33 deficient mice. (2014) (15)
Leukocyte migration to rheumatoid joints: Enzymes take over. (2006) (15)
Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments. (2012) (15)
The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. (2017) (15)
Impaired counter-regulation of interleukin-1 by the soluble IL-1 receptor type II in patients with chronic liver disease (2008) (15)
Delayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient mice (2003) (14)
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities (2020) (13)
Absence of up-regulation for a proliferation-inducing ligand in Sjögren's sialadenitis lesions. (2011) (13)
The Dermatologists' Role in Managing Psoriatic Arthritis: Results of a Swiss Delphi Exercise Intended to Improve Collaboration with Rheumatologists (2015) (13)
Excess Serum Interleukin‐18 Distinguishes Patients With Pathogenic Mutations in PSTPIP1 (2021) (13)
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration (2017) (13)
In Black Africans with rheumatoid arthritis, ACPA recognize citrullinated fibrinogen and the derived peptides α36-50Cit38,42 and β60-74Cit60,72,74, like in Caucasians. (2014) (13)
Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritis (2019) (12)
CD 14 Is an Acute-Phase Protein 1 (2004) (12)
Deficiency in IL-1 Receptor Type 2 Aggravates K/BxN Serum Transfer-Induced Arthritis in Mice but Has No Impact on Systemic Inflammatory Responses (2017) (12)
Balance between Interleukin-18 and Interleukin-18 binding protein in auto-inflammatory diseases (2022) (11)
The human intracellular interleukin 1 receptor antagonist promoter appropriately regulates gene expression in keratinocytes and gastrointestinal epithelial cells in vivo. (1999) (11)
Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort (2018) (10)
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. (2019) (10)
The effect of comedication with a csDMARD on drug retention and clinical effectiveness of anti-TNF therapy in patients with axial spondyloarthritis (2018) (10)
A systematic review of infliximab in the treatment of early rheumatoid arthritis (2007) (9)
Adult seronegative arthritis with antinuclear antibodies: a distinct group of patients with a different immunogenetic pattern from seropositive rheumatoid arthritis and a good outcome. (1996) (9)
Production of intracellular IL-1alpha, IL-1beta, and IL-1Ra isoforms by activated human dermal and synovial fibroblasts: phenotypic differences between human dermal and synovial fibroblasts. (2004) (9)
Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritis. (2021) (9)
Images in clinical medicine. Milwaukee shoulder. (2006) (9)
Genetics: Mutations in the IL1RN locus lead to autoinflammation (2009) (9)
Waldenström's Disease Complicated by Recurrent Meningococcal Arthritis (2001) (9)
[Male-type scleroderma: the role of occupational exposure]. (1992) (8)
Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints. (2021) (8)
[Efficacy of tumor necrosis factor-alpha blockade for severe sciatica?]. (2004) (8)
Intracellular IL-1 Receptor Antagonist Isoform 1 Released from Keratinocytes upon Cell Death Acts as an Inhibitor for the Alarmin IL-1α (2020) (8)
Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis. (2011) (8)
OP0030 RANDOMIZED CONTROLLED 24-WEEK TRIAL EVALUATING THE SAFETY AND EFFICACY OF BLINDED TAPERING VERSUS CONTINUATION OF LONG-TERM PREDNISONE (5 MG/D) IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED LOW DISEASE ACTIVITY OR REMISSION ON TOCILIZUMAB (2019) (8)
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab (2017) (8)
The Role of Interleukin 18/Interleukin 18-Binding Protein in Adult-Onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis (2022) (8)
The Effectiveness of Leflunomide as Co-Therapy of TNF inhibitors in Rheumatoid Arthritis . A Population Based Study (2009) (8)
Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour (2014) (8)
Production of IL-18 Binding Protein by Radiosensitive and Radioresistant Cells in CpG-Induced Macrophage Activation Syndrome (2020) (8)
Is disk-related sciatica a TNFalpha-dependent inflammatory disease? (2005) (8)
Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab (2019) (7)
THU0174 Drug retention of tofacitinib versus biologic antirheumatic agents in rheumatoid arthritis: observational data from the swiss scqm registry (2017) (7)
Adalimumab in severe and acute sciatica (2010) (7)
Grobmyer, S. R. et al. Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock: Paradoxical increase in products of caspase 1 (ICE). Mol. Med. 5, 585−594 (1999) (7)
Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals. (2020) (7)
488 ADALIMUMAB IN SEVERE AND ACUTE SCIATICA. A MULTICENTRE, RANDOMISED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED TRIAL (2010) (6)
Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling (2022) (6)
Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration (2018) (6)
IL-36–Induced Toxicity in Neonatal Mice Involves TNF-α Production by Liver Myeloid Cells (2016) (5)
Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration (2012) (5)
Lower level of synovial fluid interferon-c in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive (2003) (5)
Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the disease. (2020) (4)
Relationship between gamma-interferon and interleukin-17 in Chlamydia trachomatis reactive arthritis. (2009) (4)
The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis (2019) (4)
SAT0206 Retention of tocilizumab as monotherapy versus tnf inhibitors with conventional synthetic dmards in rheumatoid arthritis patients with inadequate response to tnf inhibitors: a study from the tocerra collaboration (2017) (4)
A systematic review of infl iximab in the treatment of early rheumatoid arthritis (2007) (4)
Structural basis of human IL-18 sequestration by the decoy receptor IL-18 binding protein in inflammation and tumor immunity (2022) (4)
Rheumatoid arthritis: from basic findings and clinical manifestations to future therapies (2017) (4)
FRI0227 Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 monarch study (2017) (4)
Non-infectious lupus pericarditis: a retrospective hospital-based observation in Yaoundé—Cameroon (2009) (4)
Coexistence of seropositive rheumatoid arthritis and SAPHO syndrome. (2013) (4)
Biological agents in the management of adult-onset Still's disease. (2019) (4)
Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach (2013) (3)
Synovial Fluid Leptin Levels and Joint Pain in End-Stage Osteoarthritis: A Potential Explanation for Increased Pain in Women and in Obese Patients. (2011) (3)
CS16-5. IL-36R Ligands are Potent Regulators of Dendritic and T Cells (2011) (3)
Commentary Physiologic role of interleukin-1 receptor antagonist (2000) (3)
The management of septic arthritis (2003) (3)
FRI0169 Smoking and Response to Rituximab in Anti-CCP Positive and Negative Rheumatoid Arthritis – Results from an International European Collaboration (2015) (3)
Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach (2022) (3)
[The differential diagnosis of tenosynovitis]. (2011) (3)
[Radiculopathy due to lumbar disc herniation]. (2009) (3)
Presence of interleukin-17 in osteoarthritis: Does it indicate a different osteoarthritis phenotype (2015) (3)
[Best practice use of corticosteroids in rheumatoid arthritis]. (2014) (2)
P024 Comparison of CCP2 and CCP3 assays in a large cohort of established rheumatoid arthritis and controls (2018) (2)
IL-33: a novel cytokine with proinflammatory properties (2007) (2)
Tocilizumab versus adalimumab for rheumatoid arthritis – Authors’ reply (2013) (2)
Mice deficient in leptin (ob/ob) or in liptin receptor (db/db) have a milder form of antigen-induced arthritis (2001) (2)
THU0130 Distinct Biomarkers Enrich for Clinical Response to Tocilizumab (TCZ) and Adalimumab (ADA) in Adacta: A Head-to-Head Monotherapy Study in Patients (PTS) with Methotrexate (MTX)-IR Rheumatoid Arthritis (RA) (2013) (2)
SAT0687 EVOLVING THE MANAGEMENT OF RHEUMATOID ARTHRITIS THROUGH DEVELOPMENT OF PRACTICAL AND EDUCATIONAL TOOLS (2019) (2)
Agreement of Mexican rheumatologists with the ASsessment in Ankylosing Spondylitis International Working Group and the EUropean League Against Rheumatism recommendations for the management of ankylosing (2006) (2)
Review The role of leptin in innate and adaptive immune responses (2006) (2)
OR6-004 – MRP8/14 promote MSU-crystal induced inflammation (2013) (2)
Randomized clinical trials in ANCA-associated vasculitis: a systematic analysis of the WHO - International Clinical Trials Registry Platform (2020) (2)
FRI0328 Fixed versus On-Flare Retreatment with Rituximab in RA – Results from the Cererra Collaboration (2014) (2)
SAT0677 Prevotella copri in individuals at risk for rheumatoid arthritis (2018) (2)
OP0099 Toll-like receptor 4 agonists MRP 8 and MRP 14 act as endogenous enhancers of MSU-crystal induced IL-1 secretion in vitro and reflect disease activity in gout patients in vivo (2013) (2)
THU0086 Seropositivity and response to RTX: Data from the cererra collaboration (2013) (2)
FRI0450 Commonalities and differences in data collection across european spondyloarthritis registries (2017) (2)
THU0131 Levels of cxcl13 and sicam1 correlate with disease activity score in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) (2018) (1)
Intra-Articular Drug Delivery Systems for Osteoarthritis Treatment (2010) (1)
FRI0582 Open-label, multicenter, dose-escalating phase ii clinical trial on the safety and efficacy of tadekinig alpha in adult onset still's disease (2017) (1)
SAT0036 Retention of Tocilizumab Therapy: A Comparison between Tocilizumab in Monotherapy and in Combination with DMARDS Based on the Tocerra Collaboration (2014) (1)
Disease-modifying antirheumatic drugs (2014) (1)
THU0075 EARLY VERSUS DELAYED START OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A PHASE 3 TRIAL OF PATIENTS NAÏVE TO METHOTREXATE TREATMENT (2019) (1)
In vitro activity of P38 MAPK inhibitor-loaded particles for the long term intra-articular treatment of osteoarthritis (2011) (1)
02.11 Il-38 is not involved in the modulation of imq-induced skin inflammation (2017) (1)
Structural basis of human IL-18 sequestration by the decoy receptor IL-18 binding protein (IL-18BP) in inflammation and tumor immunity (2022) (1)
Syndrome de Behçet (2008) (1)
IL-36: An Epithelial Cytokine Important in Psoriasis (2014) (1)
60: Atherosclerosis severity is independent of endogenous IL-33 signaling (2014) (1)
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. (2020) (1)
FRI0071 Predictors for The Development of anti-Citrullinated Protein Antibodies in Individuals Genetically at Risk for Rheumatoid Arthritis (2016) (1)
A7.13 Distinct expression of IL-36α, β, γ and their antagonists IL-36RA and IL-38 in psoriasis, rheumatoid arthritis (RA) and crohn’s disease (CD) (2016) (1)
[Redefining treatment of rheumatic arthritis with anti-cytokines]. (2007) (1)
Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational study. (2020) (1)
FRI0221 Does seropositivity influence differentially drug discontinuation of biologic antirheumatic agents with non-anti-tnf mode of action? (2017) (1)
Adipokines correlate with pain and function in lower limb osteoarthritis: different associations in hip and knee (2014) (1)
NLRP3 Q703K and TNFRSF1A R92Q mutations in a patient with auto inflammatory disease (2015) (1)
THU0177 Structural Differences Between Anti-TNF Agents are Associated with Dissimilar Rates of Secondary Loss of Effectiveness and Drug Adjustments (2013) (1)
AB0178 Menopause Is A Predictor for The Development of Anti-Citrullinated Protein Antibodies in Women at Risk for Rheumatoid Arthritis (2016) (1)
THU0245 Post-Vaccinal Arthritis in an Ebola Vaccine Trial with a Live-Attenuated Recombinant Virus Expressing the Ebola Surface Glycoprotein (RVSV-ZEBOV) (2015) (1)
OP0166 Antibodies Against Periodontal Pathogens are not Associated with Joint Swelling or Autoimmunity Associated with RA in a Cohort of Healthy Individuals at Increased Risk of Rheumatoid Arthritis (2015) (1)
P093/O16 IL-36 signaling in keratinocytes is mandatory in imiquimod-induced psoriasis in mice (2019) (1)
Statins have no effect on collagen-induced arthritis in mice (2004) (1)
[Review of the protective effects of tumor necrosis factor inhibitors in rheumatoid arthritis]. (2004) (1)
AB1368-HPR ENHANCED ROLE OF NURSES AND OTHER HEALTHCARE PROFESSIONALS (HCPS) IN THE CARE OF RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES (2019) (1)
Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis? (2008) (1)
Reply to Xie et al. about the article "Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis". (2013) (1)
Consensus guidelines on the cardiovascular risk management in patients with rheumatoid arthritis (2015) (1)
SAT0588 COMPARATIVE EFFECTIVENESS RESEARCH IN OBSERVATIONAL SETTINGS: EVALUATING TWO NEW METHODS TO ANALYSE RESPONSE RATES (2019) (1)
Response to: ‘When binary and continuous responses disagree’ by Dr Ouyang (2019) (1)
[Adverse events of biologic therapies]. (2017) (1)
Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration (2016) (1)
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update (2022) (1)
Synovial Fluid Leptin Level Is Associated with Residual Pain and Functional Disability One Year After Total Joint Arthroplasty (2012) (1)
Inflammation and autoimmune responses are independent of peripheral MHC class II expression driven by CIITA pIV in collagen induced arthritis (2011) (0)
PARE0018 ENABLING PATIENT-CENTRED CARE IN RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES (2019) (0)
FRI0099 Obese patients with rheumatoid arthritis have reduced response rates to biologic anti-rheumatic agents: a comparison between european and american ra patients (2013) (0)
Stingelin and Cem Gabay (2004) (0)
SAT0083 Tooth loss is associated with swollen joints in a cohort of healthy individuals at increased risk of developing rheumatoid arthritis (2013) (0)
This information is current as Inflammation in Mice during Endotoxemia and Sterile Cell-Derived IL-1 Receptor Antagonist Distinct Roles of Hepatocyte-and Myeloid (2010) (0)
SAT0005 DETECTION OF HIGHLY EXPANDED T CELL CLONES IN THE PERIPHERAL BLOOD OF AT RISK INDIVIDUALS FOR RHEUMATOID ARTHRITIS BEFORE THE CLINICAL ONSET OF THE DISEASE (2019) (0)
[Rheumatological arthroscopy]. (2005) (0)
Genomic / genetic / proteomic : the added value to arthritis research and treatment 1 Osteoarthritis : degeneration of matrix or cells ? (2015) (0)
Inadequate reporting of concomitant medications in rheumatology randomized controlled trials of pharmacologic interventions. (2019) (0)
FRI0070 Ultrasound doppler activity correlates with systemic autoimmunity and swollen joints in a healthy population at risk for rheumatoid arthritis (2013) (0)
Interleukin-33 expression in human arthritis (2011) (0)
Interleukin 33 expression in human arthritis (2011) (0)
Cross-talk between IL-6 trans-signaling and AIM2 inflammasome/IL-1β axes bridge innate immunity and epithelial apoptosis to promote emphysema (2022) (0)
Novel intracellular function of IL-1 receptor antagonist type 1 in endothelial cells (2003) (0)
PRECISION MEDICINE: MAXIMISING TREATMENT BENEFIT FOR RHEUMATOID ARTHRITIS PATIENTS (2016) (0)
Neuropathic Pain After Primary Total Hip and Knee Arthroplasty (2013) (0)
117 Interleukin-33 Induces the Production of Pro-inflammatory Cytokines by Mast Cells (2007) (0)
Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies (2020) (0)
[Connective tissue diseases, a matter for specialists?]. (2013) (0)
O025 Unopposed interleukin 18 signalling leads to severe toll like receptor 9-induced macrophage activation syndrome in mice (2018) (0)
A2.32 Macroautophagy proteins control dendritic cell activation and shape the TH1/TH17 response during antigen induced arthritis (2016) (0)
Treatment with anti-JAM-C antibody decreases the severity of antigen-induced arthritis (2011) (0)
FRI0088 Comparison of Rheumatoid Factor, Anti-Citrullinated Protein Antibodies, Anti-Carbamylated Protein Antibody, Anti-Peptidyl Arginine Deiminase Type-3 Antibodies and Calprotectin in Patients with Rheumatoid Arthritis and Spondyloarthritis (2016) (0)
THU0135 Shorter Drug Retention in Rheumatoid Arthritis Patients Treated with Biological Dmards in Monotherapy – an Observational Cohort Analysis (2013) (0)
AB1382 Reasons for hospitalization of patients with rheumatologic disorders (2013) (0)
O034 Expression of the decoy type 2 interleukin-1 receptor in mouse and its putative role in inflammation (2012) (0)
Mice db / db Response in on Lymphocyte Populations and Immune Indirect Effects of Leptin Receptor Deficiency and Cem (2006) (0)
Comparison of energy expenditure between patients with rheumatoid arthritis and healthy controls (0)
Author's reply (1994) (0)
Work and rehabilitation PARE0016 IMPACT OF AXIAL SPONDYLOARTHRITIS ON PATIENTS’ PROFESSIONAL LIFE: RESULTS FROM THE ONLINE SURVEY EMAS OF 638 FRENCH PATIENTS (2021) (0)
P157 Radioresistant and radiosensitive cells contribute to IL-18BP production in a model of macrophage activation syndrome (2019) (0)
[Low back pain, frequent symptoms with multiple facets]. (2009) (0)
, Ursula Lipoprotein Chlamydia trachomatis Potentiator , a Localization of Macrophage Infectivity Molecular Characterization and Subcellular (2007) (0)
OP0165 Changes in Lipoprotein(A) after Treatment with Tocilizumab (TCZ), Adalimumab (ADA), and Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA) (2014) (0)
[The state of rheumatoid arthritis, 2014]. (2014) (0)
O035 IL-33 and ST2 KO mice display different phenotypes in K/BxN serum transfer-induced arthritis (2012) (0)
AB0251 Female Reproductive Factors and the Development of Anti-Citrullinated Protein Antibodies in Women at Risk of Rheumatoid Arthritis (2015) (0)
Targeting interleukin-1 in rheumatic diseases (2007) (0)
Arthritis in Mice but Has No Impact on Aggravates K / BxN Serum Transfer-Induced Deficiency in IL-1 Receptor Type 2 (2017) (0)
Attenuates Experimental Arthritis and Cellular Immune Responses and Leptin Signaling Deficiency Impairs Humoral (2001) (0)
Interleukin-1 and its receptor antagonist in inflammatory arthritis (2015) (0)
AB0274 THE PREDICTIVE VALUE OF RHEUMATOID FACTOR, ANTI-CITRULLINATED PROTEIN ANTIBODIES, ANTI-CARBAMYLATED PROTEIN: ANTIBODIES AND ANTI-PEPTIDYL ARGININE DEIMINASE TYPE-3 ANTIBODIES, ALONE OR IN COMBINATION, ON RADIOGRAPHIC DAMAGE IN RHEUMATOID ARTHRITIS (2019) (0)
THU0238 Risk Factors for the Development of Anti-Citrullinated Protein Antibodies in Individuals Genetically at Risk for RA (2014) (0)
Concise report Absence of up-regulation for a proliferation-inducing ligand in Sjo¨gren’s sialadenitis lesions RHEUMATOLOGY (2011) (0)
Synovial tissues concentrate secreted APRIL GABAY , Cem (2019) (0)
Oligopeptide antagonist of IL-6: a novel approach to target IL-6 activities (2007) (0)
Reporting of and representativeness of race, ethnicity and socioeconomic status in systemic sclerosis randomized trials: an observational study. (2022) (0)
[Rheumatoid arthritis, methothrexate, and pulmonary fibrosis: which evidences?]. (2010) (0)
SAT0692 Breastfeeding is not associated with anti-citrullinated antibodies development in individuals at risk for rheumatoid arthritis (2018) (0)
Rheumatoid arthritis: from basic findings and clinical manifestations to future therapies (2017) (0)
Targeted IL-1 inhibition (2004) (0)
Cardiovascular risk in patients with rheumatoid arthritis (2017) (0)
Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inﬂammatory cytokines Cytokine (2016) (0)
[Ultrasound: an indispensable tool for the rheumatologist]. (2011) (0)
IL-18 Binding Protein-Producing Cells Attenuate Anemia in Murine Macrophage Activation Syndrome. (2023) (0)
Molecular characterization and subcellular localization of macrophage 1 infectivity potentiator , a Chlamydia trachomatis lipoprotein 2 3 (2007) (0)
02.12 Il-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro (2017) (0)
[Osteoarthrosis--where are we going in 2012]. (2012) (0)
Palindromic syndrome: appearance of chondrocalcinosis after 47 years of evolution. (1993) (0)
Patients With Xiap Deficiency Have Circulating Free Il-18 Which May Represent A Therapeutic Target (2017) (0)
Antibodies against periodontal pathogens are not associated with joint swelling or autoimmunity associated with RA in a cohort of healthy individuals at increased risk of rheumatoid arthritis (2015) (0)
[Spondylarthropathies in 2015]. (2016) (0)
SAT0103 Risk of Major Adverse Cardiovascular Events in A Swiss Cohort of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondylarthritis (2016) (0)
Gene therapy: will it deliver for RA? (2001) (0)
[Inflammatory arthritides pathotypes]. (2019) (0)
THU0638 CONSIDERATIONS FOR IMPROVING QUALITY OF CARE IN RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES (2019) (0)
Drugs ? Remission . Do Biologics Perform Better Than Synthetic Antirheumatic Joint Damage Progression in Patients with Rheumatoid Arthritis in Clinical (0)
PS2-035. The mouse interleukin (IL)-33 gene is expressed in cell and stimulus dependent manner from two alternative promoters (2011) (0)
FRI0187 Rituximab Done! What's Next in Rheumatoid Arthritis? A European Observational Longitudinal Study Assessing the Effectiveness of Biologics After Rituximab Treatment in Rheumatoid Arthritis (2015) (0)
AB0698 Overlaping Spondylarthritis and Periodic Autoinflammatory Syndrome? A “Bed to Bench” Story (2014) (0)
CS12-5. Which chemokine receptor should we target in Rheumatoid Arthritis (2011) (0)
OP0028 Efficacy of different doses of rituximab for the treatment of RA: Data from the cererra collaboration (2013) (0)
Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls. (2022) (0)
THU0088 Iron Deficiency and Low Erythropoietin Concentrations Are Frequent Anemia Causing Factors in Rheumatoid Arthritis (2016) (0)
Production and biological role of hepatocyte and myeloid cell-derived interleukin-1 receptor antagonist in a model of systemic inflammation (2010) (0)
61 – Cytokine neutralizers: Interleukin-1 inhibitors (2015) (0)
OP0060 Mice deficient in leptin (ob/ob) or in leptin receptor (db/db) have a milder form of antigen-induced arthritis (2001) (0)
FRI0123 Comparative effectiveness of subcutaneous versus intravenous tocilizumab in a pan-european collaboration of registries (2018) (0)
A role for leptin in immune-mediated inflammatory diseases? (2004) (0)
P097 Intracellular interleukin-1 receptor antagonist released upon cell death acts as an alarmin inhibitor in aldara cream-induced psoriasis-like skin inflammation (2019) (0)
P181 IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naïve CD4+ T cells (2012) (0)
SAT0104 Comparison of Drug Discontinuation to Inefficacy and Adverse Events Between Anti-Tnf Agents and ‘Non-Anti-Tnf Biologic Agents’ in Anti-Tnf Inadequate Responder Rheumatoid Arthritis Patients (2013) (0)
mediators of host defense : identification of early Pseudomonas aeruginosa Transcriptional response of bronchial epithelial cells to (2015) (0)
Osteoarthritis Therapy: Nanocrystal–Polymer Particles: Extended Delivery Carriers for Osteoarthritis Treatment (Small 8/2018) (2018) (0)
Special Issue "IL-1 family cytokines in host defense, inflammation and cancer". (2022) (0)
Leptin may influence RA in opposing ways : enhance the expression of Th 1 cytokines or limit the inflammatory responses (2003) (0)
AB0262 SERUM CALPROTECTIN AS A MARKER OF DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS (2019) (0)
The Relationship Between Efficacy and Toxicity in Patients with Rheumatoid Arthritis Receiving Methotrexate in Combination with Adalimumab (2015) (0)
[Soft tissue rheumatic disorders: important for general practice]. (2015) (0)
OP0182 The Impact of Statin Use on Structural Bone Damage in Rheumatoid Arthritis (2015) (0)
[The management of osteoarticular problems by internal/general practitioners is inadequate. Is this a problem?]. (2005) (0)
SP0002 Therapy of Rheumatoid Arthritis (2013) (0)
A10.02 Deficiency in IL-1 receptor type 2 aggravates K/BXN serum transfer-induced arthritis in mice, but has no effect in endotoxemia (2016) (0)
OP0093 Il-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro (2017) (0)
Secreted IL-1Ra exerts a protective effect on atherosclerotic lesion development in apolipoprotein-E-deficient mice (2003) (0)
A systematic review of in fl iximab in the treatment of early rheumatoid arthritis (2007) (0)
68 Biological role of myeloid cell-derived interleukin-1 receptor antagonist in collagen-induced arthritis (2008) (0)
ID: 147: IL-1 cytokines – The balance between agonists and antagonists in health and disease (2015) (0)
FRI0701 Does parity influence joint damage progression in women with rheumatoid arthritis? (2017) (0)
IL-36 signaling ampliﬁes Th1 responses by enhancing proliferation and Th1 polarization of naive CD4 (cid:1) T cells (2012) (0)
Production of interleukin (IL)-1 receptor antagonist by human articular chondrocytes (2002) (0)
AB0004 Characterization of Putative Pre-RA Signatures by Transcriptome Analysis (2015) (0)
ID: 129: Role of the IL-36 pathway in inflammatory responses in mouse neonates (2015) (0)
A5.19 In African Patients with Rheumatoid Arthritis ACPA Recognise Citrullinated Fibrinogen and the Immunodominant Epitopes Borne by the Fibrin Peptides α36–50 and β60–74, Like in Caucasians (2013) (0)
THU0110 The importance of sustained remission for longterm outcomes in patients with rheumatoid arthritis (2017) (0)
SAT0229 Effectiveness of Repeated Courses of Rituximab in RA – Results from the Cererra Collaboration (2014) (0)
67 Biological role of hepatocyte-derived interleukin-1 receptor antagonist in a model of systemic inflammation (2008) (0)
A5.12 Atherosclerosis severity is independent of endogenous IL-33 signalling (2015) (0)
Arthritis and Rheumatism (2006) (0)
SAT0318 Association between joint pain severity and serum leptin levels in hand osteoarthritis (2013) (0)
SP0142 Interleukin-36: A key cytokine for innate and adaptive immune responses (2013) (0)
Contributors (2012) (0)
Predictors of infection in patients treated with rituximab for autoimmune diseases (0)
Effectiveness Of Tocilizumab In Monotherapy and In Combination With Different Synthetic Dmards: A Registry-Based Comparison Study (2013) (0)
ID: 133: IL-36 acts on myeloid cells and exerts stronger stimulatory effects compared to IL-1 in M2-polarized macrophages (2015) (0)
The cytosolic DNA sensor AIM2 promotes Helicobacter‐induced gastric pathology via the inflammasome (2023) (0)
A1.23 Macroautophagy deficiency in dendritic cells exacerbates antigen-induced arthritis (2015) (0)
[Rheumatology in the aged]. (2010) (0)
Authors' replies (1995) (0)
ID: 138: Deficiency in IL-1 receptor type 2 aggravates K/BxN serum transfer-induced arthritis in mice, but has no effect in endotoxemia (2015) (0)
[Rheumatic diseases and infections]. (2006) (0)
THU0202 Comparative effectiveness of tocilizumab as monotherapy versus tnf inhibitors in combination with conventional synthetic disease modifying antirheumatic drugs in bio-naÏve patients with rheumatoid arthritis (2018) (0)
35 – Biologic Agents (2012) (0)
Intracellular IL-1 receptor antagonist (icIL-1Ra1) does not antagonize growth inhibitory effects of pre-IL-1α in SaOS-2 cells (2005) (0)
Interleukin-1 Receptor Antagonist Isoforms in Collagen-Induced Arthritis (1999) (0)
Effects of leflunomide on interleukin-1 receptor antagonist (IL-1Ra) synthesis in chondrocytes and synovial fibroblasts (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Cem Gabay?

Cem Gabay is affiliated with the following schools:

Cem Gabay's Academic­Influence.com Rankings

Cem Gabay's Degrees

Similar Degrees You Can Earn

Why Is Cem Gabay Influential?

Cem Gabay's Published Works

Published Works

What Schools Are Affiliated With Cem Gabay?

Cem Gabay's AcademicInfluence.com Rankings